Bausch Health Companies Inc.
BHCAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 29, 2026 | Jefferies | Young LI | $8.00(-10%) | $8.89 | StreetInsider |
| Oct 8, 2026 | RBC Capital | Doug Miehm | $9.00(+46%) | $6.15 | StreetInsider |
| Jan 7, 2026 | Truist Financial | Les Sulewski | $8.00(+5%) | $7.63 | TheFly |
| Dec 8, 2025 | Barclays | Glen Santangelo | $8.00(+17%) | $6.82 | TheFly |
| Oct 23, 2024 | RBC Capital | Douglas Miehm | $10.00(+24%) | $8.06 | TheFly |
| Jul 25, 2024 | Truist Financial | Les Sulewski | $7.00(+23%) | $5.69 | TheFly |
| Jul 10, 2024 | Raymond James | Michael Freeman | $8.00(+11%) | $7.19 | TheFly |
| Apr 29, 2024 | Piper Sandler | David Amsellem | $9.00(+3%) | $8.78 | StreetInsider |
| Apr 23, 2024 | RBC Capital | Doug Miehm | $11.00(+30%) | $8.45 | StreetInsider |
| Apr 11, 2024 | Jefferies | Glen Santangelo | $16.00(+73%) | $9.28 | StreetInsider |
| Apr 5, 2024 | RBC Capital | Doug Miehm | $12.00(+19%) | $10.05 | StreetInsider |
| Sep 9, 2022 | Piper Sandler | $6.00(-10%) | $6.70 | Benzinga | |
| Jul 26, 2022 | RBC Capital | $12.00(+37%) | $8.73 | Benzinga | |
| May 13, 2022 | RBC Capital | $17.00(+63%) | $10.45 | Benzinga |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| RBC Capital | maintain | Sector Perform | Oct 29, 2026 |
| Jefferies | maintain | Hold | Oct 29, 2026 |
| RBC Capital | maintain | Sector Perform | Apr 27, 2026 |
| Barclays | maintain | Equal Weight | Feb 25, 2026 |
| Truist Securities | maintain | Hold | Jan 7, 2026 |
| RBC Capital | maintain | Sector Perform | May 2, 2025 |
| Jefferies | downgrade | Buy →Hold | Feb 6, 2025 |
| RBC Capital | maintain | Sector Perform | Jan 30, 2025 |
| RBC Capital | maintain | Sector Perform | Nov 1, 2024 |
| RBC Capital | maintain | Sector Perform | Aug 2, 2024 |
| Piper Sandler | downgrade | Neutral →Underweight | Aug 2, 2024 |
| Truist Securities | maintain | Hold | Jul 25, 2024 |
| RBC Capital | maintain | Sector Perform | Apr 23, 2024 |
| RBC Capital | maintain | Sector Perform | Apr 12, 2024 |
| RBC Capital | maintain | Sector Perform | Apr 5, 2024 |
| RBC Capital | maintain | Sector Perform | Feb 23, 2024 |
| Jefferies | upgrade | Hold →Buy | Sep 20, 2023 |
| TD Cowen | downgrade | Outperform →Market Perform | Jun 16, 2023 |
| Jefferies | maintain | Buy | May 22, 2023 |
| RBC Capital | maintain | Sector Perform | May 5, 2023 |
| Piper Sandler | maintain | Neutral | Sep 9, 2022 |
| RBC Capital | maintain | Sector Perform | Sep 1, 2022 |
| BMO Capital | maintain | Market Perform | Aug 10, 2022 |
| RBC Capital | maintain | Sector Perform | Aug 10, 2022 |
| JP Morgan | downgrade | Overweight →Neutral | Jul 29, 2022 |
Earnings History
Next report: Feb 17, 2027 · EPS est. $1.34| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Oct 28, 2026 | $1.77 | $1.25 | $2.89B | $2.72B |
| Jul 29, 2026 | $1.26 | $0.96 | $2.81B | $2.59B |
| Apr 29, 2026 | $0.78 | $0.81 | $2.47B | $2.37B |
| Feb 18, 2026 | $1.08 | $1.21 | $2.79B | $2.73B |
| Oct 29, 2025 | $1.16 | $1.07 | $2.68B | $2.71B |
| Jul 30, 2025 | $0.90 | $0.97 | $2.53B | $2.58B |
| Apr 30, 2025 | $0.59 | $0.83 | $2.26B | $2.48B |
| Feb 19, 2025 | $1.15 | $1.65 | $2.56B | $2.29B |
News
LAVAL, QC, Nov. 6, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, will present a research poster at the American Association for the Study of Liver Diseases' The Liver Meeting® 2026, November 5–9 in Denver, Colorado. The study highlights the substantial mortality and rehospitalization among patients hospitalized with severe alcohol-associated hepatitis (AH).
Bausch Health Companies Inc. BHC emphasized sustained operational growth, stronger cash generation and improved financial flexibility during its third-quarter 2026 earnings call. Management raised its full-year guidance while outlining anticipated headwinds from Xifaxan pricing changes and inventory adjustments.
Here is how Bausch Health (BHC) and Bausch + Lomb (BLCO) have performed compared to their sector so far this year.
Bausch Health shares jump 9% as Q3 earnings top estimates, driven by Xifaxan-led Salix growth, improved profitability and raised 2026 guidance.
Bausch Health Companies Inc. ( BHC ) Q3 2026 Earnings Call October 28, 2026 5:00 PM EDT Company Participants Garen Sarafian Thomas Appio - CEO & Director Jean-Jacques Charhon - Executive VP & CFO Conference Call Participants Umer Raffat - Evercore ISI Institutional Equities, Research Division Douglas Miehm - RBC Capital Markets, Research Division Presentation Operator Greetings, and welcome to the Bausch Health Third Quarter 2026 Earnings Conference Call. As a reminder, this conference is being …
Although the revenue and EPS for Bausch (BHC) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Bausch Health (BHC) came out with quarterly earnings of $1.77 per share, beating the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $1.16 per share a year ago.
Bausch Health Cos NYSE: BHC raised its full-year 2026 outlook for the second consecutive quarter after reporting third-quarter growth across its operating segments, led by Salix and supported by international operations and Solta Medical.
LAVAL, QC, Oct. 28, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that its subsidiary, Bausch Health Americas, Inc., will issue an irrevocable notice of redemption dated as of October 29, 2026 pursuant to which it will redeem approximately $643 million of aggregate principal amount of its outstanding 8.500% Senior Notes due 2027, CUSIP Nos. 91911XAW4 and U9098VAP7 (the "Notes"), using cash on hand.
LAVAL, QC, Oct. 28, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase its common shares ("Common Shares") for a total aggregate purchase price of up to US$50 million (the "Share Repurchase Program"). The primary objective of the Share Repurchase Program is to manage the potential dilutive impact of future employee equity-based compensation.
Third Quarter Consolidated Revenues of $2.94 billion, up 10% on a Reported basis and 8% on an Organic1 basis over the prior year period GAAP Net Income Attributable to Bausch Health of $436 million and GAAP Net Income of $446 million GAAP Earnings per Diluted Share Attributable to Bausch Health of $1.15 compared to $0.48 in the prior year period; Adjusted Earnings per Diluted Share1 of $1.77 compared to $1.16 in the prior year period, an increase of 53% Consolidated Adjusted EBITDA Attributable …
Bausch Health reports Q3 2026 results on Oct. 28, with $2.75 billion in expected sales. Explore key segment drivers and mixed earnings surprise history.
Bausch Health Cos (NYSE: BHC - Get Free Report) and Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations. Profitability This table compares
Shares of Bausch Health Cos Inc. (NYSE: BHC - Get Free Report) have received a consensus rating of "Hold" from the seven brokerages that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and one has assigned a strong buy recommendation to
Bausch Health Cos Inc. (NYSE: BHC - Get Free Report)'s stock price gapped up prior to trading on Monday. The stock had previously closed at $6.04, but opened at $6.27. Bausch Health Cos shares last traded at $5.9550, with a volume of 211,220 shares traded. Analyst Ratings Changes BHC has been the topic of several research
LAVAL, QC, Oct. 12, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), announced results from a multicenter pilot study evaluating a standardized clinical pathway for cirrhosis management demonstrated improved adherence to evidence-based monitoring and treatment practices across community gastroenterology settings. The findings will be presented as a poster at the American College of Gastroenterology (ACG…
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company, and its parent company, Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced that Bausch + Lomb Board of Directors Chairman Thomas J. Appio has been appointed interim chief executive officer, effective immediately. Appio will continue to serve as CEO of Bausch Health while assuming leadership of Bausch + Lomb. Appio was appointed chairman of the Bausch + Lomb Board of Dir.
LAVAL, QC, Oct. 6, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2026 financial results after market close on Wednesday, October 28, 2026. Bausch Health will host a live conference call and webcast at 5:00 p.m.
ABT, CORT, PGEN and BHC offer low-beta healthcare exposure as rate-hike fears and market volatility persist.
BHC, CDNA, DOLE and CHEF offer defensive exposure as consumer confidence falls amid inflation and geopolitical tensions.